| Latest Forum Topics / Others |
 Post Reply
|
|
George Soros Fund Favors Pharmaceutical
|
|
|
billywows
Elite |
16-Aug-2006 22:50
|
|
x 0
x 0 Alert Admin |
Yup, I still sticking with CSM for the time being .... Shiok! |
| Useful To Me Not Useful To Me | |
|
ten4one
Master |
16-Aug-2006 13:14
|
|
x 1
x 0 Alert Admin |
Ok, so Mr Soros Fund is buying pharm. stocks that doesn't mean that you and I should follow. First and foremost, you and I may have zero knowledge about these stocks - eg. how they make money and what they really do and their risks, competitors and so on and so forth.............. Therefore, always be yourself and trust your own judgements. If you can't do that forget about the Stock Markets! Cheers!!!!!!! |
| Useful To Me Not Useful To Me | |
|
|
|
|
billywows
Elite |
15-Aug-2006 23:23
|
|
x 0
x 0 Alert Admin |
Good time to spot a buy a good pharmaceutical buy now! ------------------------------------- UPDATE 1-Soros Fund favors pharmaceutical stocksMon Aug 14, 2006 7:35pm ET
 (New throughout) By Joel Rothstein WASHINGTON, Aug 14 (Reuters) - A quarterly report on Monday by influential investor George Soros showed new or bigger stakes in several pharmaceutical companies and reduced holdings in technology bellwethers Cisco Systems Inc. (CSCO.O: Quote, Profile, Research) and Microsoft Corp. (MSFT.O: Quote, Profile, Research) The filing with the U.S. Securities and Exchange Commission disclosed the long stock positions, or bets that stock prices will rise, of Soros Fund Management LLC as of June 30. Quarterly SEC disclosures from institutional investors exclude short positions, or bets that stocks will decline, that the portfolio may hold. New disclosed holdings as of that date included 3.3 million shares in NPS Pharmaceuticals Inc (NPSP.O: Quote, Profile, Research), 783,000 shares in GTC Biotherapeutics Inc (GTCB.O: Quote, Profile, Research), over 700,000 shares in Celgene Corp (CELG.O: Quote, Profile, Research), 343,000 shares in Hana Biosciences Inc (HNAB.O: Quote, Profile, Research), 280,000 shares in Human Genome Sciences Inc (HGSI.O: Quote, Profile, Research), 285,000 shares in Indenix Pharmaceuticals Inc (IDIX.O: Quote, Profile, Research) and an increase to 413,000 shares from 257,000 shares in Nektar Therapeutics (NKTR.O: Quote, Profile, Research) since Soros filed a March 31 report with the SEC. The filing showed a reduced stake in Cisco to 123,000 shares from 699,000 shares and a cut in its Microsoft holdings to 126,000 shares from 252,000 shares since March 31. The fund sharply increased its stakes in Axcelis Technologies Inc. (ACLS.O: Quote, Profile, Research), and Extreme Networks Inc (EXTR.O: Quote, Profile, Research) and also added 100,000 shares in Oracle Corp (ORCL.O: Quote, Profile, Research) to its disclosed portfolio. |
| Useful To Me Not Useful To Me | |